Restaging rectal cancer following neoadjuvant chemoradiotherapy

World J Gastrointest Oncol. 2023 May 15;15(5):700-712. doi: 10.4251/wjgo.v15.i5.700.

Abstract

Correct tumour restaging is pivotal for identifying the most personalised surgical treatment for patients with locally advanced rectal cancer undergoing neoadjuvant therapy, and works to avoid both poor oncological outcome and overtreatment. Digital rectal examination, endoscopy, and pelvic magnetic resonance imaging are the recommended modalities for local tumour restaging, while chest and abdominal computed tomography are utilised for the assessment of distant disease. The optimal length of time between neoadjuvant treatment and restaging, in terms of both oncological safety and clinical effectiveness of treatment, remains unclear, especially for patients receiving prolonged total neoadjuvant therapy. The timely identification of patients who are radioresistant and at risk of disease progression remains challenging.

Keywords: Colonoscopy; Computed tomography scan; Endorectal ultrasound; Locally advanced rectal cancer; Pelvic magnetic resonance imaging; Restaging.

Publication types

  • Review